9 February 2022 - BioMarin Pharmaceutical today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the rare paediatric disease priority review voucher it obtained in November 2021 for a lump sum payment of $110,000,000. 

BioMarin was awarded the voucher when it received approval of Voxzogo (vosoritide) for Injection, indicated to increase linear growth in paediatric patients with achondroplasia five years of age and older with open epiphyses (growth plates).

Read BioMarin press release